Teva Pharmaceutical Industries delivered one of its strongest quarters in years, sending shares of TEVA surging roughly 12% after the company reported first-quarter 2026 results that beat Wall Street expectations on nearly every measure — profits, revenue, and earnings per share.
For millions of Americans who rely on Teva for affordable generic drugs and specialty medicines, the results signal a company that is not just financially recovering but actively growing into a more innovative force in healthcare.
The Numbers
Net income soared 72% to $369 million, up from $214 million in the same period a year earlier, driven by a 25.6% jump in operating income to $652 million.  Earnings per share came in at $0.53, beating the analyst forecast of $0.48 — a positive surprise of more than 10%. 
Total revenue reached $3.98 billion, up 2.3% from $3.89 billion a year ago.  That headline number tells only part of the story. The real engine of growth was Teva’s innovative drug portfolio, which is rapidly shifting the company away from its traditional dependence on generics.
Blockbuster Brands Leading the Way
Teva’s three key innovative brands — AUSTEDO, AJOVY, and UZEDY — collectively grew 41% year over year to $838 million in combined revenue.  Each product is treating conditions that affect everyday people: movement disorders, migraines, and schizophrenia.
AUSTEDO, used to treat chorea associated with Huntington’s disease and tardive dyskinesia, generated $578 million in revenue, up 41% year over year. UZEDY, a long-acting injectable treatment for schizophrenia, posted $63 million in sales — a 62% jump. AJOVY, Teva’s migraine prevention therapy, contributed $196 million, up 35%. 
UZEDY has established itself as the fastest-growing long-acting injectable antipsychotic on the market, with months of therapy up 75% year over year.  For patients managing serious mental illness, that kind of growth reflects real-world adoption — not just Wall Street metrics.
Free cash flow increased 76% year over year, giving the company significantly more financial flexibility heading into the rest of 2026. 
A $700 Million Bet on the Brain
Teva also announced a $700 million acquisition of Emalex Biosciences, aimed at expanding its neurology pipeline.  The deal is set to add an NDA-ready Tourette syndrome therapy to Teva’s neuroscience portfolio, with the transaction expected to close by the third quarter of 2026. 
The move signals that Teva is not content to rest on its generics heritage. Under its “Pivot to Growth” strategy, the company is pushing deeper into specialty medicine — areas where brand loyalty, clinical differentiation, and pricing power are far stronger than in the commodity generics market.
What’s Ahead
Teva maintained its full-year 2026 revenue outlook of $16.4 billion to $16.8 billion.  The company also reaffirmed its ambition to reach a 30% non-GAAP operating margin and approximately $700 million in net savings by 2027.  The board instructed management to begin planning a potential share repurchase program, signaling confidence in the company’s financial trajectory. 
For everyday consumers, the picture is straightforward: the company that makes many of the generic drugs Americans depend on is getting healthier, investing in new treatments, and returning value — all at the same time.
JBizNews Desk
© JBizNews.com. All rights reserved. This article is original reporting by JBizNews Desk. Unauthorized reproduction or redistribution is strictly prohibited.
